Working… Menu
Trial record 31 of 34 for:    Han weidong

SHR-1210 Alone or in Combination With Decitabine in Relapsed or Refractory Hodgkin Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03250962
Recruitment Status : Recruiting
First Posted : August 16, 2017
Last Update Posted : April 1, 2019
Information provided by (Responsible Party):
Han weidong, Chinese PLA General Hospital

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : July 21, 2022
Estimated Study Completion Date : March 21, 2025